

Investor Webinar – Tuesday 6 May @ 2:30pm AEST

Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to invite shareholders and interested parties to an Investor Webinar on **Tuesday, 6 May 2025, at 2:30pm AEST**.

Managing Director Tom Spurling will discuss Nova Eye Medical's recently released March 2025 Quarterly Activities and Cashflow Report.

Webinar Details

- **Date:** Tuesday, 6 May 2025
- **Time:** 2:30pm AEST
- **Presenter:** Tom Spurling, Nova Eye Medical Managing Director
- **Registration Link:** <https://bit.ly/4iBITzO>

Participants will have the opportunity to submit questions before the webinar by emailing mflynn@nova-eye.com or during the live Q&A session.

The Company encourages investors to attend this session to gain further insights into the Company's quarterly results which show record US sales, revenue growth, and improved glaucoma profitability. In addition, the Company has identified additional opportunities to expand the application of the proprietary iTrack™ technology into ocular drug delivery markets, setting the stage for future growth.

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

-ends-

For more information:

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com